The Boston College Board of Trustees elected eight new board members to four-year terms at its annual meeting earlier this summer. The new trustees come from a range of professional backgrounds, with ...
Lilly’s oral SERD imlunestrant joins elacestrant in the US market for ESR1-mutated advanced breast cancer, but imlunestrant’s trial design raises questions about its place in current practice.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback